Compositions and methods for the treatment of traumatic optic neuropathy

The method of any one of the previous claims, wherein the TON is caused by direct injury or indirect injury to the subject.

The method of any one of the previous claims, wherein the peptide is administered daily for 2 weeks or more.

The method of any one of the previous claims, wherein the peptide is administered daily for 12 weeks or more.

The method of any one of the previous claims, wherein the treating or preventing comprises the treatment or prevention of one or more signs or symptoms of TON comprising one or more of vision loss, blurred vision, scotoma, decreased color sensation, uveitis, optic neuritis, eye pain, optic nerve avulsion, optic nerve transection, optic nerve sheath hemorrhage, orbital hemorrhage, choroidal rupture, and commotio retinae.

The method of any one of the previous claims, wherein the subject is a mammal.

The method of any one of the previous claims, wherein the peptide is administered orally, topically, intranasally, systemically, intravenously, subcutaneously, intraperitoneally, intradermally, intraocularly, ophthalmically, iontophoretically, transmucosally, intravitreally, or intramuscularly.

The method of any one of the previous claims, further comprising separately, sequentially, or simultaneously administering an additional treatment to the subject.

The method of any one of the previous claims, wherein the pharmaceutically acceptable salt comprises a mono-acetate salt, a bis-acetate salt, a tri-acetate salt, a tartrate salt, a mono-trifluoroacetate salt, a bis-trifluoroacetate salt, a tri-trifluoroacetate salt, a mono-hydrochloride (“mono-HCl”) salt, a bis-hydrochloride (“bis-HCl”) salt, a tri-hydrochloride (“tri-HCl”) salt, a mono-tosylate salt, a bis-tosylate salt, or a tri-tosylate salt.

A method for improving visual function in a subject having traumatic optic neuropathy (TON), the method comprising administering to the subject a therapeutically effective amount of the peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof.

The method of claim 41 or 42, wherein hypothermia is induced in the subject.

A method of promoting retinal ganglion cell (RGC) survival or increasing neurite outgrowth of an RGC comprising contacting an RGC with an effective amount of the peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof.

Use of a composition in the preparation of a medicament for treating or preventing traumatic optic neuropathy (TON) in a subject in need thereof, wherein the composition comprises a therapeutically effective amount of the peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof.

Use of a composition in the preparation of a medicament for improving visual function in a subject having traumatic optic neuropathy (TON), wherein the composition comprises a therapeutically effective amount of the peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof.

Use of a composition in the preparation of a medicament for promoting retinal ganglion cell (RGC) survival or increasing neurite outgrowth of an RGC, wherein the composition comprises an effective amount of the peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof.

A peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof, for use in treating or preventing traumatic optic neuropathy (TON) in a subject in need thereof.

A peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof, for use in improving visual function in a subject having traumatic optic neuropathy (TON).

A peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof, for use in promoting retinal ganglion cell (RGC) survival or increasing neurite outgrowth of an RGC.

A method for reducing the risk of TON in a subject that has experienced a traumatic injury, the method comprising administering to the subject a therapeutically effective amount of the peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof.